Prospective comparison of allogeneic stem cell transplantation vs conventional therapy
| Authors . | MDS risk . | Age, median (range), y . | Donor (matched) vs no donor . | LFS . | OS . |
|---|---|---|---|---|---|
| Robin et al84 | IPSS: intermediate-2 or high risk with poor cytogenetics or platelet TD or CMML | 50-70 | n = 112 vs n = 50 | na | At 4 y: 37% vs 15%; P = .02 |
| Nakamura et al (BMT-CTN 1102)85 | IPSS: intermediate-2 and high risk | 50-75 | n = 260 vs n = 124 | At 3 y: 35.8% vs 20.6%; P = .03 | At 3 y: 47.9% vs 26.6%; P = .001 |
| Kröger et al (VidazaAllo-Study)86 | IPSS-R: intermediate-2 or high risk or intermediate-2 with poor cytogenetics | 50-70 | n = 81 vs n = 27 [no donor: 5-aza treated] | At 3 y: 34% vs 0%; P < .0001 | At 3 y: 50% vs 32%; P = .12 |
| Yu et al88 | IPSS: low, intermediate-1 + 2 | 19-63 | randomization allo: n = 91 no allo: n = 91 | At 3 y: 74.7% vs 53.9%; P < .05 | At 3 y: 79% vs 56%; P < .05 |
| Authors . | MDS risk . | Age, median (range), y . | Donor (matched) vs no donor . | LFS . | OS . |
|---|---|---|---|---|---|
| Robin et al84 | IPSS: intermediate-2 or high risk with poor cytogenetics or platelet TD or CMML | 50-70 | n = 112 vs n = 50 | na | At 4 y: 37% vs 15%; P = .02 |
| Nakamura et al (BMT-CTN 1102)85 | IPSS: intermediate-2 and high risk | 50-75 | n = 260 vs n = 124 | At 3 y: 35.8% vs 20.6%; P = .03 | At 3 y: 47.9% vs 26.6%; P = .001 |
| Kröger et al (VidazaAllo-Study)86 | IPSS-R: intermediate-2 or high risk or intermediate-2 with poor cytogenetics | 50-70 | n = 81 vs n = 27 [no donor: 5-aza treated] | At 3 y: 34% vs 0%; P < .0001 | At 3 y: 50% vs 32%; P = .12 |
| Yu et al88 | IPSS: low, intermediate-1 + 2 | 19-63 | randomization allo: n = 91 no allo: n = 91 | At 3 y: 74.7% vs 53.9%; P < .05 | At 3 y: 79% vs 56%; P < .05 |
CMML, chronic myelomonocytic anemia; na, not assessed.